Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. CEO Troy Wilson will join a panel discussion titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET. A live audio webcast will be accessible via the Investors section of Kura's website, with a replay available shortly after the event. Kura focuses on precision medicines for cancer, currently advancing drug candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancer types.

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET / 7:20 a.m. PT on Wednesday, August 11, 2021.

A live audio webcast of the panel will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS and/or PIK3CA-dependent HNSCC. The Company is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When is Kura Oncology participating in the Wedbush PacGrow Healthcare Virtual Conference?

Kura Oncology is participating in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021.

Who from Kura Oncology will be speaking at the conference?

Troy Wilson, CEO of Kura Oncology, will be speaking at the conference.

What time is Kura Oncology's panel discussion at the conference?

Kura Oncology's panel discussion is scheduled for 10:20 a.m. ET on August 11, 2021.

Where can I listen to the Kura Oncology conference panel?

You can listen to Kura Oncology's conference panel live on their website in the Investors section.

What is Kura Oncology's focus in cancer treatment?

Kura Oncology focuses on precision medicines targeting cancer signaling pathways, with candidates like KO-539 and Tipifarnib in clinical trials.